MercadoLibre (MELI) Is Down 6.6% After Boosting 2026 Argentina Investment Plan - What's Changed

MercadoLibre, Inc. -0.20%

MercadoLibre, Inc.

MELI

1715.52

-0.20%

  • In March 2026, MercadoLibre said it would invest US$3.40 billion in Argentina in 2026, about 30% more than its previously outlined 2025 spending, to expand logistics, add distribution centers, enhance its technology platform, grow Mercado Pago and create nearly 2,000 local jobs.
  • This larger commitment in its home market comes as the company faces rising competition, thinner margins and heightened scrutiny of its profitability strategy across Latin America.
  • Now we’ll explore how this stepped-up Argentina investment, amid margin pressure and Brazil competition, may influence MercadoLibre’s investment narrative.

Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

MercadoLibre Investment Narrative Recap

To own MercadoLibre, you have to be comfortable with a company that is still prioritizing ecosystem expansion over near term margins, especially in logistics and fintech. The US$3.40 billion Argentina plan reinforces that story, but does not change the near term catalyst many are watching: signs of margin stabilization after recent compression. The biggest immediate risk remains that rising credit losses and competitive spending needs, particularly in Brazil, keep profitability under pressure longer than expected.

The announcement most tied to this Argentina push is Morgan Stanley’s recent comment that higher logistics and marketing spend is likely to pressure margins. That view lines up with a larger Argentina budget that includes new distribution centers and technology upgrades, which could weigh on operating margins before any scale benefits show up. How quickly these investments support Mercado Pago engagement and commerce growth is central to the near term margin and earnings debate.

Yet investors should also be aware that rising logistics and credit costs in volatile markets could...

MercadoLibre's narrative projects $46.9 billion revenue and $5.1 billion earnings by 2028. This requires 24.8% yearly revenue growth and an earnings increase of about $3.0 billion from $2.1 billion today.

Uncover how MercadoLibre's forecasts yield a $2805 fair value, a 68% upside to its current price.

Exploring Other Perspectives

MELI 1-Year Stock Price Chart
MELI 1-Year Stock Price Chart

Some of the lowest ranked analysts were already assuming around US$39.3 billion of revenue and US$4.3 billion of earnings by 2028, which paints a much more cautious picture than the consensus and highlights how differently you and others might weigh the risk that rising logistics costs outpace revenue growth over time, especially after this new Argentina commitment that both narratives have not yet fully reflected.

Explore 28 other fair value estimates on MercadoLibre - why the stock might be worth just $2188!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your MercadoLibre research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free MercadoLibre research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MercadoLibre's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

  • The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.